| Gene symbol | E7 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001526.4 (7604..7900) | dbXrefs | |
| Description | transforming protein E7 | ||||
| Gene symbol | MAGEA1 | Synonyms | CT1.1, MAGE1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | MAGE family member A1 | ||||
| Gene symbol | MAGEC2 | Synonyms | CT10, HCA587, MAGEE1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq27.2 | dbXrefs | |
| Description | MAGE family member C2 | ||||
| Gene symbol | PRAME | Synonyms | CT130, MAPE, OIP-4, OIP4 | Type of gene | protein-coding |
| Chromosome | 22 | Map location | 22q11.22 | dbXrefs | |
| Description | PRAME nuclear receptor transcriptional regulator | ||||
| GTO ID | GTC3529 |
| Trial ID | NCT05973487 |
| Disease | Head and Neck Cancer | Melanoma | Anogenital Cancer | Cervical Cancer | HPV-Associated Cancer | Lung Non-Small Cell Carcinoma | Ovarian Cancer |
| Altered gene | MAGE-A1|E7|PRAME|MAGE-C2 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TSC-204-A0201|TSC-204-C0702|TSC-200-A0201|TSC-203-A0201|TSC-204-A0101|TSC-201-B0702 |
| HLA | HLA-A*02:01|HLA-C*07:02|HLA-A*01:01|HLA-B*07:02 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors |
| Year | 2023 |
| Country | United States |
| Company sponsor | TScan Therapeutics, Inc. |
| Other ID(s) | TSCAN-002 |
| Cohort1: TSC-204-A0201_MAGE-A1 | |||||||||
|
|||||||||
| Cohort2: TSC-204-C0702_MAGE-A1 | |||||||||
|
|||||||||
| Cohort3: TSC-200-A0201_HPV-16 E7 | |||||||||
|
|||||||||
| Cohort4: TSC-203-A0201_PRAME | |||||||||
|
|||||||||
| Cohort5: TSC-204-A0101_MAGE-A1 | |||||||||
|
|||||||||
| Cohort6: TSC-201-B0702_MAGE-C2 | |||||||||
|
|||||||||